Haleon Updates Total Voting Rights Following Share Capital Adjustment

An update from Haleon PLC ( (GB:HLN) ) is now available.

Haleon plc, a global consumer health specialist listed on the LSE and NYSE, develops and markets over-the-counter health products across oral health, vitamins and supplements, pain relief, respiratory and digestive health, and therapeutic skin categories. Its portfolio features widely recognised brands including Sensodyne, Voltaren, Panadol, Advil, Centrum, Theraflu, parodontax, Polident and Otrivin, underpinned by an emphasis on trusted science and broad international reach.

The company reported that as of 28 February 2026 it has issued 8,952,353,648 ordinary shares, of which 43,969,144 are held in treasury, leaving 8,908,384,504 shares carrying voting rights. This updated share count provides the reference denominator for investors and other stakeholders when assessing disclosure thresholds under the UK’s transparency rules, ensuring accurate reporting of significant shareholdings and changes in ownership in Haleon.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £421.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Neutral.

The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon plc is a global consumer health company listed in London and New York, focused on delivering everyday health products across oral care, vitamins, minerals and supplements, pain relief, respiratory and digestive health, and therapeutic skin health. Its portfolio includes long-established brands such as Sensodyne, Voltaren, Panadol, Advil, Centrum, Theraflu, parodontax, Polident and Otrivin, supported by science-led innovation and large-scale international distribution.

The group targets mass-market consumers seeking over-the-counter remedies and preventative health products, positioning itself as a leading player in non-prescription healthcare worldwide. By leveraging brand recognition and broad category coverage, Haleon aims to capture recurring demand in key health segments and maintain a strong presence in pharmacies, supermarkets and digital retail channels across major global markets.

Average Trading Volume: 16,812,172

Technical Sentiment Signal: Buy

Current Market Cap: £36.13B

Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.